A novel scenario in the therapeutic management of anemia of chronic kidney disease: placement and use of roxadustat
F Locatelli, M Ravera, C Esposito, G Grandaliano… - Journal of …, 2024 - Springer
Anemia is a frequent and early chronic kidney disease (CKD) complication. Its management
is currently based on oral or intravenous iron supplements, erythropoiesis-stimulating …
is currently based on oral or intravenous iron supplements, erythropoiesis-stimulating …
Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease
P Natale, SC Palmer, A Jaure… - Cochrane Database …, 2022 - cochranelibrary.com
Background Anaemia occurs in chronic kidney disease (CKD) and is more prevalent with
lower levels of kidney function. Anaemia in CKD is associated with death related to …
lower levels of kidney function. Anaemia in CKD is associated with death related to …
Iron parameters in patients treated with roxadustat for anemia of chronic kidney disease
Roxadustat is a novel agent with a distinct mechanism of action compared to erythropoiesis-
stimulating agents (ESAs) and a potentially different combination of effects on iron …
stimulating agents (ESAs) and a potentially different combination of effects on iron …
Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta …
A Sackeyfio, RD Lopes, CP Kovesdy… - Clinical Kidney …, 2024 - academic.oup.com
Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are oral
alternatives to current standard-of-care treatments for anaemia in chronic kidney disease …
alternatives to current standard-of-care treatments for anaemia in chronic kidney disease …
Safety of roxadustat versus erythropoiesis-stimulating agents in patients with anemia of non-dialysis-dependent or incident-to-dialysis chronic kidney disease: pooled …
J Barratt, F Dellanna, J Portoles, G Choukroun… - Advances in …, 2023 - Springer
Introduction This study was conducted to elucidate the safety of roxadustat, an oral
medication, in patients with non-dialysis-dependent (NDD) or incident dialysis dialysis …
medication, in patients with non-dialysis-dependent (NDD) or incident dialysis dialysis …
[HTML][HTML] Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
Anemia is common in patients with chronic kidney disease (CKD) and is mainly caused by
insufficient production of erythropoietin from fibrotic kidney. Because anemia impairs quality …
insufficient production of erythropoietin from fibrotic kidney. Because anemia impairs quality …
Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies
J Glaspy, NY Gabrail, P Locantore‐Ford… - American Journal of …, 2023 - Wiley Online Library
Anemia is a common side effect of myelosuppressive chemotherapy; however,
chemotherapy‐induced anemia (CIA) management options are suboptimal. We evaluated …
chemotherapy‐induced anemia (CIA) management options are suboptimal. We evaluated …
[HTML][HTML] Iron Supplements Concomitant within Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitors in the Treatment of Chronic Kidney Disease Anemia
X Wang, C Wei, D Zhao, X Sun, F Zhu, Y Mei, Q Ma… - Kidney …, 2023 - karger.com
Background: Anemia is a common and important complication in patients with chronic
kidney disease (CKD). Accordingly, the current treatment is based on erythropoiesis …
kidney disease (CKD). Accordingly, the current treatment is based on erythropoiesis …
The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors
F Locatelli, L Del Vecchio, S Elliott - Clinical Kidney Journal, 2023 - academic.oup.com
The discovery and development of erythropoiesis-stimulating agents was a journey lasting
more than a century, leading to the cloning and approval of recombinant human …
more than a century, leading to the cloning and approval of recombinant human …
A spotlight on using HIF-PH inhibitors in renal anemia
M Odawara, H Nishi, M Nangaku - Expert Opinion on …, 2024 - Taylor & Francis
ABSTRACT Introduction Erythropoiesis-stimulating agents (ESAs) together with iron
supplementation had been the standard treatment for anemia in chronic kidney disease …
supplementation had been the standard treatment for anemia in chronic kidney disease …